TRIM44 and Miyoshi myopathy: To investigate the impact of TRIM44 on patients treated with Bortezomib, we analyzed single-cell RNA-sequencing data from bone marrow-mononuclear cells (BM-MNCs) of 18 treatment-naive MM patients.